Bylund James
SEC CIK 1849642 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| RGEN | REPLIGEN CORP | COO | 25.4K | — | $1.68M | 32 | 2022-02-17 | 2026-03-05 |
Most active insiders at RGEN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Hunt Anthony | Dir | — | $7.01M |
| 2 | Loeillot Olivier | CEO, Dir | — | $4.19M |
| 3 | Bylund James | COO | — | $331.3K |
| 4 | Garland Jason K | CFO | — | $185.8K |
| 5 | DAWES KAREN A | Dir | — | $44.3K |
| 6 | Douglass Brian Robb | Chief PRODUCT Off | — | — |
| 7 | Pax Margaret | Dir | — | — |
| 8 | Hughes Violetta | CAO | — | — |
| 9 | Mhatre Rohin | Dir | — | — |
| 10 | Konstantinov Konstantin | Dir | — | — |
Transactions 32
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-23 | 2026-03-05 | RGEN | REPLIGEN CORP | Bylund James | COO | A - Grant | $0.00 | +7,751 | 25.4K | +44% | $0 |
| 2026-03-05 | 2026-03-04 | RGEN | REPLIGEN CORP | Bylund James | COO | A - Grant | $0.00 | +125 | 17.7K | +0.7% | $0 | |
| 2026-03-05 | 2026-03-04 | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $125.84 | -62 | 17.7K | -0.3% | -$7,802 | |
| M | 2026-03-03 | 2026-02-27+ | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $126.39 | -3,911 | 17.6K | -18% | -$494.3K |
| 2025-11-19 | 2025-11-18 | RGEN | REPLIGEN CORP | Bylund James | COO | S - Sale | $151.21 | -2,191 | 21.5K | -9% | -$331.3K | |
| 2025-04-02 | 2025-04-01 | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $128.50 | -454 | 23.7K | -2% | -$58.3K | |
| 2025-03-20 | 2025-03-13 | RGEN | REPLIGEN CORP | Bylund James | COO | A - Grant | $0.00 | +381 | 24.3K | +2% | $0 | |
| 2025-03-20 | 2025-03-13 | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $142.44 | -175 | 24.2K | -0.7% | -$24.9K | |
| D | 2025-03-04 | 2025-03-03 | RGEN | REPLIGEN CORP | Bylund James | COO | A - Grant | $0.00 | +6,435 | 25.2K | +34% | $0 |
| D | 2025-03-04 | 2025-03-03 | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $155.38 | -1,239 | 24.0K | -5% | -$192.5K |
| 2025-02-28 | 2025-02-27 | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $156.54 | -1,285 | 18.8K | -6% | -$201.2K | |
| 2025-02-25 | 2025-02-24 | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $164.74 | -543 | 20.0K | -3% | -$89.5K | |
| 2024-04-04 | 2024-04-02 | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $182.95 | -444 | 20.6K | -2% | -$81.2K | |
| 2024-03-07 | 2024-03-07 | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $195.72 | -1,206 | 21.0K | -5% | -$236.0K | |
| M | 2024-03-06 | 2024-03-04+ | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $194.14 | -219 | 22.3K | -1.0% | -$42.5K |
| 2024-03-05 | 2024-03-01 | RGEN | REPLIGEN CORP | Bylund James | COO | A - Grant | $0.00 | +50 | 22.5K | +0.2% | $0 | |
| 2024-03-04 | 2024-03-01 | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $191.79 | -820 | 22.4K | -4% | -$157.3K | |
| 2024-03-04 | 2024-02-29 | RGEN | REPLIGEN CORP | Bylund James | COO | A - Grant | $0.00 | +404 | 23.2K | +2% | $0 | |
| D | 2024-02-29 | 2024-02-27 | RGEN | REPLIGEN CORP | Bylund James | COO | A - Grant | $0.00 | +8,691 | 22.8K | +61% | $0 |
| D | 2024-02-26 | 2024-02-23 | RGEN | REPLIGEN CORP | Bylund James | COO | S - Sale+OE | $198.08 | -4,373 | 14.1K | -24% | -$866.2K |
| D | 2024-02-26 | 2024-02-23 | RGEN | REPLIGEN CORP | Bylund James | COO | M - OptEx | $94.33 | +940 | 18.5K | +5% | +$88.7K |
| 2023-04-04 | 2023-04-04 | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $163.45 | -334 | 17.6K | -2% | -$54.6K | |
| DM | 2023-03-06 | 2023-03-02+ | RGEN | REPLIGEN CORP | Bylund James | COO | A - Grant | $0.00 | +8,973 | 18.1K | +98% | $0 |
| D | 2023-03-06 | 2023-03-03 | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $188.00 | -210 | 17.9K | -1% | -$39.5K |
| 2023-02-28 | 2023-02-28 | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $173.44 | -594 | 9,139 | -6% | -$103.0K | |
| D | 2022-08-04 | 2022-08-03 | RGEN | REPLIGEN CORP | Bylund James | COO | S - Sale+OE | $240.40 | -2,000 | 9,733 | -17% | -$480.8K |
| D | 2022-08-04 | 2022-08-03 | RGEN | REPLIGEN CORP | Bylund James | COO | M - OptEx | $94.33 | +2,000 | 11.7K | +21% | +$188.7K |
| 2022-04-04 | 2022-04-01 | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $188.02 | -335 | 9,733 | -3% | -$63.0K | |
| D | 2022-02-28 | 2022-02-24 | RGEN | REPLIGEN CORP | Bylund James | COO | A - Grant | $0.00 | +3,366 | 10.3K | +49% | $0 |
| D | 2022-02-28 | 2022-02-24 | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $189.21 | -188 | 10.1K | -2% | -$35.6K |
| 2022-02-22 | 2022-02-17 | RGEN | REPLIGEN CORP | Bylund James | COO | F - Tax | $182.42 | -334 | 6,890 | -5% | -$60.9K | |
| 2022-02-22 | 2022-02-17 | RGEN | REPLIGEN CORP | Bylund James | COO | A - Grant | $0.00 | +900 | 7,224 | +14% | $0 |
Purchase Sale Sale after option exercise All abbreviations